Annals of Nuclear Medicine

, Volume 29, Issue 6, pp 482–488 | Cite as

Role of 64CuCl2 PET/CT in staging of prostate cancer

  • Enza Capasso
  • Silvia Durzu
  • Sara Piras
  • Shahin Zandieh
  • Peter Knoll
  • Alexander Haug
  • Marcus Hacker
  • Carlo Meleddu
  • Siroos MirzaeiEmail author
Original Article



The presence of an elevated copper concentration in cancer cells may be potentially used to differentiate healthy from transformed cells. In this study, we aimed to look at the possible role of 64CuCl2 PET/CT in staging of patients with prostate cancer (PC).


Seven patients affected by histologically confirmed PC have been prospectively enrolled. Three patients underwent adrenal deprivation therapy (ADT) at time of imaging. The remaining four patients had no ADT, surgery, or external beam radiation therapy (EBRT). In all patients, up to three 64CuCl2 PET/CT scans 10 min, 1 h and 3 h (and an additional scan 24 h in 2 patients) after administration of mean 339 MBq 64CuCl2 were performed and analyzed for presence of disease. Additionally, dosimetric calculations were performed. All patients underwent a multiparametric magnetic resonance imaging (mMRI) for confirmation of disease.


Lesions specifically in the pelvic area could be easily delineated, which was due to the absence of urinary excretion of the tracer. 64CuCl2 uptake was higher in primary tumors of patients without ADT than in patients under bicalutamide therapy. In two patients with suspected lymphadenopathy at MRI (>10 mm diameter), there was no enhanced 64CuCl2 uptake. In other two patients, there was focal enhanced uptake in involved pelvic lymph nodes, one of which with a normal size of <10 mm.


The preliminary results of this study show a high uptake of 64CuCl2 in PC and involved regional lymph nodes indicating to a great potential of 64CuCl2 PET/CT for primary staging of patients with prostate cancer.


64CuCl2 PET/CT Prostate cancer Staging Androgen deprivation therapy (ADT) 



We thank the staff of Regional Oncological Hospital, U.O.C. Nuclear Medicine, Cagliari for their excellent technical assistance and generous support.


  1. 1.
    Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European cancer observatory. Eur J Cancer. 2013;. doi: 10.1016/j.ejca.2013.09.002.Google Scholar
  2. 2.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23–34.PubMedCrossRefGoogle Scholar
  3. 3.
    Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.PubMedCrossRefGoogle Scholar
  4. 4.
    National Cancer Institute, Prostate Cancer., Access 5.11. 2014.
  5. 5.
    Surcel CI, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, et al. Preferences in management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. BJU Int. 2014;. doi: 10.1111/bju.12796.PubMedGoogle Scholar
  6. 6.
    Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59:962–77.PubMedCrossRefGoogle Scholar
  7. 7.
    Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(Suppl 1):S5–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Seino H, Ono S, Miura H, Morohashi S, Wu Y, Tsushima F, et al. Incidental prostate 18F-FDG uptake without calcification indicates the possibility of prostate cancer. Oncol Rep. 2014;31:1517–22.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, et al. Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1356–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895–904.PubMedCrossRefGoogle Scholar
  12. 12.
    Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Sparks R, Peng F. Positron emission tomography of altered copper metabolism for metabolic imaging and personalized therapy of prostate cancer. J. Radiol. Radiat. Ther. 2013;1:1015.Google Scholar
  14. 14.
    Peng F, Lu X, Janisse J, Muzik O, Shields AF. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med. 2006;47:1649–52.PubMedGoogle Scholar
  15. 15.
    Cai H, Wu JS, Muzik O, Hsieh JT, Lee RJ, Peng F. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med. 2014;55:622–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Stabin MG, Sparks RB, Crowe E. Olinda/EXM: the second generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMedGoogle Scholar
  17. 17.
    Dobruch J, Piotrowicz S, Skrzypczyk M, Gołąbek T, Chłosta P, Borówka A. Clinical value of extended pelvic lymph node dissection in patients subjected to radical prostatectomy. Wideochir Inne Tech Malo Inwazyjne. 2014;9:64–70.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Tiguert R, Gheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ, et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology. 1999;53:367–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Brogsitter C, Zöphel K, Kotzerke J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(Suppl 1):S18–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, et al. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int. 2012;110:1666–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68 Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833–40.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2015

Authors and Affiliations

  • Enza Capasso
    • 1
  • Silvia Durzu
    • 2
  • Sara Piras
    • 2
  • Shahin Zandieh
    • 3
  • Peter Knoll
    • 4
  • Alexander Haug
    • 5
  • Marcus Hacker
    • 5
  • Carlo Meleddu
    • 1
  • Siroos Mirzaei
    • 4
    Email author
  1. 1.Regional Oncological HospitalU.O.C. Nuclear MedicineCagliariItaly
  2. 2.Regional Oncological HospitalS.C. Medical PhysicsCagliariItaly
  3. 3.Institute of Radiology and Nuclear Medicine, Hanusch HospitalTeaching Hospital of Medical University of ViennaViennaAustria
  4. 4.Department of Nuclear Medicine with PET-centerWilhelminenspitalViennaAustria
  5. 5.Division of Nuclear MedicineMedical University of ViennaViennaAustria

Personalised recommendations